Leerink Partners Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Outperform
Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an ...
Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)
In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals REGN +0.75% Get Free Report has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, ...
Morningstar2d
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman
SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting ... a significant drop in its stock price on October 31, 2024.
Mena FN5d
Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns And Investor Lawsuit– Hagens Berman
(MENAFN- GlobeNewsWire - Nasdaq) SAN FRANCISCO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) is facing ... drop in its stock price on October 31, 2024.
Seeking Alpha4d
Notable analyst calls this week: AMD, Skyworks and Nike stocks among top picks
Riley Securities also downgraded Skyworks to Neutral from Buy, while Mizuho downgraded the stock to Neutral from ... Underperform rating but upped the price target to $60 from $28.